<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320826">
  <stage>Registered</stage>
  <submitdate>12/11/2009</submitdate>
  <approvaldate>15/02/2010</approvaldate>
  <actrnumber>ACTRN12610000152022</actrnumber>
  <trial_identification>
    <studytitle>Rescue percutaneous coronary intervention (PCI) after fibrinolytics for the treatment of heart attack</studytitle>
    <scientifictitle>Randomised clinical trial to evaluate ACUITY bleeding rates in  ST elevation myocardial infarction (STEMI) patients undergoing rescue percutaneous coronary intervention (PCI) post failed fibrinolysis, treated with bivalirudin or heparin and a glycoprotein IIb/IIIa inhibitor.</scientifictitle>
    <utrn />
    <trialacronym>RESCUE PCI</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>STEMI</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment with bivalirudin (Angiomax). The recommended dosage of Angiomax for patients undergoing PCI is an intravenous (IV) bolus dose of 0.75 mg/kg followed by an IV infusion at a rate of 1.75 mg/kg/hour for the duration of the procedure, or for up to four hours post-PCI, as clinically indicated.</interventions>
    <comparator>Herparin plus one of 3 glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide or tirofiban). The dose of heparin will be tailored to the clinical setting. In patients undergoing PCI, target activated clotting time (ACT) may be as low as 200 seconds with adjunctive IIb/IIIa inhibitors and this can be achieved with a weight adjusted heparin bolus at 3070 U/kg heparin. Abciximab will be given as 0.25 mg/kg bolus 10-60 min before intervention, then 0.125mcg/kg/min (max 10 mcg/min) continuous infusion for 12 hrs. Eptifibatide is given as an intravenous bolus of 180 microgram/kg administered immediately prior to the procedure, followed by a second bolus of 180 microgram/kg ten minutes after the first bolus injection. Simultaneously with the first bolus, a continuous infusion should be started at a dose of 1.0 -2.0 microgram/kg/minute. The infusion is continued until hospital discharge or up to a maximum of 18 to 24 hours post-PCI. A minimum of 12 hours of infusion is recommended. Tirofiban is administered intravenously, initially at 0.4 mcg/kg/min for 30 min; then 0.1 mcg/kg/min; usual duration is 48-108 hours. The infusion may continue through angiography and up to 12-24 hours.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>ACUITY (major and minor) bleeding at 30 days.</outcome>
      <timepoint>30 days following randomisation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Infarct size assessed as the area under the curve (AUC) of creatine kinase-myocardial band isoenzyme (CKMB) levels.</outcome>
      <timepoint>Infarct size assessed following randomisation and before discharge from hospital.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patients with STEMI presenting within 12 hours of onset of symptoms
2. Administration of fibrinolytic therapy and failed reperfusion</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Contraindication to fibrinolytic therapy
2. Known hypersensitivity or contraindication to bivalirudin, heparin or glycoprotein inhibitors (GPI).
3. Severe renal impairment
4. Inability to give informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>410</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor John French</primarysponsorname>
    <primarysponsoraddress>Liverpool Hospital
Department of Cardiology
Elizabeth St, Liverpool
NSW 2170</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>The Medicines Company</fundingname>
      <fundingaddress>8 Sylvan Way, Parsippany, NJ 07054</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine which of two different intravenous anticoagulant strategies, currently in clinical use, is the safest and will have less associated bleeding complications. The study aims to test the hypothesis that use of bivalirudin has a lower rate of bleeding complications compared to heparin and glycoprotein IIb/IIIa inhibitor use.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>18/12/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John French</name>
      <address>Department of Cardiology
Liverpool Hospital
Locked Bag 7103
Liverpool BC
NSW 1871</address>
      <phone>+61 2 9828 3000</phone>
      <fax />
      <email>j.french@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>John French</name>
      <address>Department of Cardiology
Liverpool Hospital
Locked Bag 7103
Liverpool BC
NSW 1871</address>
      <phone>+61 2 9828 3000</phone>
      <fax />
      <email>j.french@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Maria Gonzalez</name>
      <address>Department of Cardiology
Liverpool Hospital
Locked Bag 7103
Liverpool BC
NSW 1871</address>
      <phone>+61 2 9828 3000</phone>
      <fax />
      <email>maria.gonzalez2@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>